FDA
-
-
-
-
-
-
-
Biohaven Announces Scientific Leadership Transitions
-
-
-
-
-
-
-
Biohaven shares clinical data on epilepsy drug opakalim
-
-
-
-
-
-
-
Biohaven reports early patient data from protein degrader programs
-
-
-
-
-
-
-
Biohaven Pharmaceutical Holding (BHVN) PT Lowered to $26 at Morgan Stanley
-
-
-
-
-
-
-
JPMorgan on Biohaven Pharmaceutical (BHVN): 'expect the stock to be under some pressure'
-
-
-
-
-
-
-
Truist: 'QURE Update Minimal Read-Through To PTCT & WVE, In Our View'
-
-
-
-
-
-
-
Biohaven Reports Second Quarter 2025 Financial Results and Recent Business Developments
-
327,799 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

